Skip to content
HowShorted

EAGLE PHARMACEUTICALS, INC. short interest in 2020

In 2020, EAGLE PHARMACEUTICALS, INC.'s disclosed short interest ran from 12.68% of shares outstanding on 15 Jan 2020 to 11.45% on 31 Dec 2020, a change of -1.23 percentage points. The year's high was 16.79% on 30 Sep 2020 and its low 11.45% on 31 Dec 2020, averaging 13.52% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.57 days on 31 Jul 2020. Full history: EAGLE PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for EAGLE PHARMACEUTICALS, INC. in 2020

2020 in figures

Start of year
12.68% (15 Jan 2020)
End of year
11.45% (31 Dec 2020)
Change
-1.23 pp
High
16.79% (30 Sep 2020)
Low
11.45% (31 Dec 2020)
Average
13.52%
Highest days to cover
22.57 (31 Jul 2020)
SEC filings marked
8

Every report in 2020

EAGLE PHARMACEUTICALS, INC. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202012.68%10.78
31 Jan 202013.65%19.99
14 Feb 202013.18%17.38
28 Feb 202013.44%11.85
13 Mar 202013.69%6.9910-K filed, results (8-K)
31 Mar 202013.85%9.40
15 Apr 202013.90%14.38
30 Apr 202013.33%13.45
15 May 202013.26%14.4810-Q filed, results (8-K)
29 May 202013.28%15.41
15 Jun 202013.45%11.50
30 Jun 202014.61%10.27
15 Jul 202015.13%11.50
31 Jul 202015.20%22.57
14 Aug 202014.49%9.7610-Q filed, results (8-K)
31 Aug 202014.73%15.78
15 Sep 202013.18%8.56
30 Sep 202016.79%11.61
15 Oct 202013.75%13.99
30 Oct 202012.59%13.69
13 Nov 202011.99%12.2110-Q filed, results (8-K)
30 Nov 202011.48%18.79
15 Dec 202011.46%14.93
31 Dec 202011.45%10.34

See also: EAGLE PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.